Simon Mayr retweeted
Fantastic presentation by Karim Fizazi! PEACE-1 at 7.7 years: adding abiraterone to ADT + docetaxel improved median OS to 6.2 vs 4.4 years (HR 0.68) in de novo mCSPC. Durable benefit from upfront intensification! @myESMO #ESMO26 @oncoalert
Simon Mayr retweeted
FOURLIGHT-1 beautifully presented by @antgiorda
Fulvestrant + atirmociclib (cdk4i) vs Fulvestrant or exemestane + everolimus
All had prior CDK 4/6i
PFS 9.9 vs 6.6 HR 0.60 p=0.0007
@OncoAlert @DFCI_BreastOnc
Simon Mayr retweeted
Encouraging OS results in neuroendocrine prostate cancer at #ESMO26!
#KEYNOTE-365 evaluated pembrolizumab + carboplatin/etoposide vs chemotherapy alone.
• mOS: 10.2 vs 7.1 months (HR 0.33)
• rPFS: 5.1 vs 4.0 months (HR 0.66)
• PD-L1 CPS ≥1: mOS 11.0 vs 4.8 months (HR 0.16)
No new safety signals observed.
@myESMO @oncoalert
Simon Mayr retweeted
⏳ 4 weeks to go!
2nd Annual Women in Hematology US Focus Meeting
📍 Hilton Austin, TX
📅 Nov 6–7, 2026
26 expert faculty, 8 sessions, led by wonderful co-chairs @sanamloghavi @SoniSmithMD @DrKrinaPatel
#WomenInHematology #Hematology #projectmanagement
Simon Mayr retweeted
As amazing as the @_MDEducation EU focus meeting was, Lisbon and the company was also special. @matteolambe @hoperugo @JavierCortesMD #bcsm
That's a wrap on our inaugural Breast Cancer EU Focus Meeting in Lisbon.
Two days at the SANA Malhoa with a great faculty from across Europe and the US, covering everything from HER2+ and TNBC to HR+ early and metastatic disease, ADC sequencing and risk-reducing strategies for BRCA1/2 carriers. The panel discussions were exactly what we hoped for: open, practical, and very much driven by the fellows in the room.
A big thank you to our co-chairs @VKaklamani and @JavierCortesMD for building such a strong program, and to all faculty for their time and contributions. Also to @TinnaCriss1, who managed this meeting from first draft to final session - a great job on a first edition.
Looking forward to the 2027 edition.
#BreastCancer #MedicalEducation #Oncology #Lisbon
Simon Mayr retweeted
Second day of @_MDEducation Breast Cancer EU Focus Meeting with answers to the predictive value of TILs in TNBC and the future of ADCs @lab_kok @hoperugo
Simon Mayr retweeted
What an amazing first day of @_MDEducation Breast Cancer EU meeting in beautiful Lisbon @JavierCortesMD @hoperugo @BianchiniGP @lab_kok @matteolambe @BarbaraPistill2 #bcsm
Simon Mayr retweeted
Such a great meeting with very timely topics @jhaveri_komal
Uploading the highlight video from the Breast Cancer Meeting two weeks ago — still feeling the thrill! The amazing feedback from the faculty made it even more special. Already excited for next year! ✨#breastcancer #livemeetings
Simon Mayr retweeted
Lung Cancer US Focus Meeting 2026 is officially complete — and what a fantastic event it was in Nashville!
A huge thank you to our chairs @StephenVLiu and @CharuAggarwalMD , faculty, fellows, supporters, attendees, and the on site team!
Already looking forward to next year!
Simon Mayr retweeted
Just 2 weeks to go until the Lung Cancer US Focus Meeting 2026 - and I’m really looking forward to it!
We’re bringing together a brilliant faculty and a highly engaged audience for two days of meaningful, discussion-driven exchange #LungCancer #projectmanagement #eventmanagement
Simon Mayr retweeted
Here’s the #BreastCancer Research Digest-a summary of last week’s publications from select high-impact journals (March 27th - April 3rd, 2026). #ClinicalResearch #CancerTreatment #BCSM #BreastCancerResearch #BreastCancer
Simon Mayr retweeted
After three incredible years, the Women in IBD EU Focus Meeting returns for its 4th edition in Rome! 🇮🇹
Co-chaired by @MLongMD and Joana Torres, MD and packed with an international faculty of outstanding women in IBD.
November 13–14, 2026 | Rome, Italy
🔗 md-education.com/women-in-ib…
Simon Mayr retweeted
At our Inaugural Breast Cancer US Focus Meeting, Ian Krop, MD highlighted the rapidly evolving HER2-positive breast cancer treatment landscape.
He returns for our 2nd Annual Meeting on April 24 - 25, 2026.
md-education.com/breast-canc…
Simon Mayr retweeted
Another outstanding session at the CLL & Lymphoma EU Focus Meeting 2026 in Lisbon. Session VI covered the full patient journey in CLL treatment sequencing. From front-line targeted therapy to bispecific antibodies, CARs, and managing double exposed and double refractory disease. #MDEducation
Simon Mayr retweeted
Two experts. Two approaches. One great debate. 🎯 @LiaPalomba and @YucaiWangMD faced off on CAR-T vs Bispecifics in Mantle Cell Lymphoma. Sign up for the recordings: links.md-education.com/Cell_…
#MDEducation @Daver_Leukemia @JoshuaRichterMD
Simon Mayr retweeted
Exciting News! Our Inaugural CLL & Lymphoma EU Focus Meeting 2026 is CME accredited 👏🏻
Earn 10.0 ECMEC®s while learning from Europe's leading experts in CLL and lymphoid malignancies. Chaired by Prof. Stephan Stilgenbauer & Prof. Franck Morschhauser, two of the most respected names in the field.
🔗 Register now: md-education.com/cll-lymphom…
#MDEducation #Hematology @HemostasisToday @Jessica_Okosun @tobyeyre82 @gloria_iacoboni @MJerkeman
Simon Mayr retweeted
We wrapped up an extraordinary three days in Puerto Rico with a deep dive into CML and CLL.
Yesterday, we heard from global experts like Daniel DeAngelo, MD, and @mjmauroMD on the nuances of CML frontline and relapse management, followed by a comprehensive CLL update from William Wierda, MD.
Sign up for the recordings: links.md-education.com/pan_h…
#MDEducation @Daver_Leukemia @Ramikomrokji
Simon Mayr retweeted
Empowering Women in Medicine: Mentorship and Growth was one of the most inspiring sessions at the Women In Hematology US Focus Meeting 2025. Featuring @LNastoupilMD, Neha Mehta-Shah, MD, MSCI, @DrKrinaPatel, and Ross Levine, MD, this session highlighted women leading transformative advances in myeloma research, lab-based innovation, and collaborative initiatives with disease organizations such as LRF.
Truly inspiring from start to finish.
🎥 Recordings are available to watch here: academy.md-education.com/cou…
#MDEducation @sanamloghavi
Simon Mayr retweeted
Dr. Stephan Stilgenbauer highlights why the CLL & Lymphoma EU Focus Meeting 2026 is a unique opportunity for both established experts and early-career clinicians. Its intimate format enables direct, face-to-face exchange with a wide range of key opinion leaders from across the globe. 🌏
This year’s program showcases key advances in disease biology and patient care, spanning trial design, MRD assessment, treatment resistance, and treatment sequencing.
Read the full agenda and join us: md-education.com/cll-lymphom…
🗓 March 13–14, 2026 | 📍 Lisbon, Portugal










































